ReviewLife (Basel, Switzerland)2025
Differential Expression of Maternal Plasma microRNAs and Their Respective Gene Targets Can Predict Early Fetal Growth Restriction.
Review in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- miR-146a/b-5p-IRAK1-NF-κB Axis Regulates Unexplained Recurrent Spontaneous Abortion.Journal of molecular recognition : JMR · 2026Article
- Multi-tissue miRNA networks in preterm birth: from molecular mechanisms to precision medicine.Frontiers in immunology · 2026Review
- Research on the Role of Autophagy in Vascular Endothelial Cells in the Healing of Chronic Refractory Wounds.Biologics : targets & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fetal growth restriction (FGR) is a condition where the fetus does not reach its genetically predetermined size, affecting 1 in 10 pregnancies and contributing to up to 50% of all stillbirths before 34 weeks of gestation. Current diagnostic methods primarily involve ultrasound and Doppler assessments, yet there is growing interest in identifying biomarkers for early diagnosis and improved management. This systematic review examined the role of microRNAs (miRNAs) in the pathogenesis of FGR, focusing on their potential as non-invasive biomarkers. MicroRNAs are small, non-coding RNAs that regulate gene expression. This review systematically assessed studies investigating the differential expression of miRNAs in maternal blood, serum, and plasma samples from FGR-affected pregnancies. A total of nine studies met the inclusion criteria, which showed the differential expression of a total of 48 miRNAs. miR-16-5p was consistently upregulated in multiple studies and trimesters. miR-590-3p and miR-206 were consistently upregulated in multiple trimesters. The common gene targets of these miRNAs are VEGF, PIGF, and MMP9. The downregulation of these genes contributes to impaired angiogenesis, trophoblast invasion, placental function, and fetal growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.